Overview
Portfolio
More
ALIVE - Israel HealthTech Fund
Tel Aviv, Israel
ALIVE is a mid-to-late stage HealthTech fund focused on Israeli health technology companies developing medical devices, diagnostics, digital health, healthcare IT, and AI/ML solutions. They leverage an exclusive ecosyste...
Portfolio
12+
Employees
5+
Founded
2020
AUM
≈ $350.0M
Investment focus
Stages
Series B → Series C+
Industries
HardwareArtificial IntelligenceDigital Health
Geographic scope
Israel
Fund details
Funds
ALIVE Growth Fund III
Vintage 2025 • $200.0M
ALIVE Israel HealthTech Fund
Vintage 2020 • $150.0M
Sources
ALIVE - Israel HealthTech Fund
ALIVE is a mid-to-late stage HealthTech fund focused on Israeli health technology companies developing medical devices, diagnostics, digital health, healthcare IT, and AI/ML solutions. They leverage an exclusive ecosystem of hospitals, HMOs and financial partners to accelerate clinical validation, market entry and scaling, aiming to bring advanced technologies to patients' bedside.
Portfolio
12+
Employees
5+
Founded
2020
AUM
≈ $350.0M
Funds
ALIVE Growth Fund III · Vintage 2025 • $200.0M
ALIVE Israel HealthTech Fund · Vintage 2020 • $150.0M
Stages
Series B → Series C+
Industries
HardwareArtificial IntelligenceDigital Health
Geographic scope
Israel
Sources
Showing 10 of 10 matched portfolio companies
Append Medical develops a transcatheter Left Atrial Appendage closure system that utilizes a proprietary vacuum mechanism to invert and ligate LAA tissue without implanting any devices in the heart. This approach significantly reduces the risks of device-related thromboembolism and peri-device leakage, addressing the heightened stroke risk faced by patients with non-valvular atrial fibrillation.
Funding: $13.2M
Rough estimate of the amount of funding raised
Funding: $13.2M
Rough estimate of the amount of funding raised
The startup develops a virtual reality medical platform that integrates augmented and virtual reality capabilities to replace traditional surgical microscopes. This technology enables real-time data integration, enhancing surgical efficiency, patient safety, and overall surgical outcomes across various therapeutic areas.
Funding: $47.5M
Rough estimate of the amount of funding raised
Funding: $47.5M
Rough estimate of the amount of funding raised
Provides a healthcare-focused cybersecurity platform that uses Network Detection and Response (NDR) technology to identify, prevent, and mitigate cyber threats targeting medical devices and patient data. The platform offers automated device discovery, real-time risk assessment, and network segmentation to protect sensitive information and ensure compliance with regulatory standards.
Funding: $37.0M
Rough estimate of the amount of funding raised
Funding: $37.0M
Rough estimate of the amount of funding raised
Innovalve develops catheter-based heart valve therapies to treat patients with valvular heart disease. Their technology aims to improve patient outcomes by providing less invasive options for valve replacement and repair.
Funding: $10.5M
Rough estimate of the amount of funding raised
Funding: $10.5M
Rough estimate of the amount of funding raised
Navina offers an AI-driven platform that consolidates unstructured patient data into actionable insights, enabling clinicians to efficiently review patient records and optimize care during visits. This technology addresses the challenge of fragmented data by providing a single source of truth, enhancing diagnostic accuracy and improving value-based care workflows.
Funding: $45.0M
Rough estimate of the amount of funding raised
Funding: $45.0M
Rough estimate of the amount of funding raised
Nevia utilizes a machine learning platform to analyze vaginal secretions for the early detection of diseases such as ovarian cancer, which is often diagnosed at late stages. By enabling timely diagnosis, Nevia aims to improve survival rates and empower women to take control of their health.
Funding: $5.1M
Rough estimate of the amount of funding raised
Funding: $5.1M
Rough estimate of the amount of funding raised
NOVA is a platform that connects creative professionals with job opportunities by allowing users to showcase their portfolios and post job listings tailored to specific project needs. It addresses the challenge of finding qualified talent quickly in the creative industry, having generated over $10 million for creatives and facilitated 17,000 job postings across more than 500 cities globally.
Funding: $1.8M
Rough estimate of the amount of funding raised
Funding: $1.8M
Rough estimate of the amount of funding raised
OncoHost utilizes its PROphet® platform, which employs bioinformatic proteomic pattern recognition and AI, to generate a personalized PROphet® score that predicts the efficacy of PD-1/PD-L1 inhibitors in cancer therapy. This blood-based test provides actionable insights for clinicians, enabling tailored treatment strategies that aim to improve patient outcomes before therapy initiation.
Funding: $50.1M
Rough estimate of the amount of funding raised
Funding: $50.1M
Rough estimate of the amount of funding raised
Vessi Medical has developed a patent-protected cryo spray technology specifically for ablating urological tissues in hollow and humid organs, offering a minimally invasive alternative to traditional surgical procedures. This approach reduces complications, eliminates the need for general anesthesia in some cases, and lowers healthcare costs associated with the treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC).
Funding: $18.2M
Rough estimate of the amount of funding raised
Funding: $18.2M
Rough estimate of the amount of funding raised
Wisdo is an AI-driven social health platform that connects users with personalized peer support and skill-building groups to combat loneliness and social isolation. By leveraging clinically-proven methodologies, Wisdo improves mental health outcomes, reporting a 60% reduction in loneliness and a $1,900 annual medical cost reduction per user.
Funding: $5.0M
Rough estimate of the amount of funding raised
Funding: $5.0M
Rough estimate of the amount of funding raised
Showing 2 of 2 unmatched portfolio companies